Mood stabilizers (lithium, valproate, lamotrigine) work through distinct mechanisms to reduce mood cycling and are essential for bipolar management. Lithium requires monitoring of renal and thyroid function.
From your study of bipolar I disorder, you know the clinical challenge: acute manic and depressive episodes must be treated, but the real burden of the illness comes from chronic cycling that, untreated, tends to worsen in severity and frequency over time. Antidepressants alone are insufficient and may even destabilize the cycle; what is needed are agents that dampen the amplitude of mood swings across both poles. That is the defining clinical purpose of mood stabilizers — they treat acute episodes and, critically, prevent future ones.
Lithium is the prototypical mood stabilizer and remains uniquely effective for mania and suicide prevention. Its mechanism is not fully understood, but two targets stand out. The inositol depletion hypothesis posits that lithium inhibits recycling of inositol, a precursor for the IP3 second-messenger system that drives excessive neuronal signaling during mania. Separately, lithium inhibits GSK-3β, a kinase involved in intracellular signaling and neuroprotection. Lithium has a narrow therapeutic window (serum levels of 0.6–1.2 mEq/L for maintenance), meaning the difference between a therapeutic and toxic dose is small. Long-term use can impair renal concentrating ability (causing nephrogenic diabetes insipidus) and suppress thyroid function, hence the need for regular monitoring of renal and thyroid function. Despite these management requirements, lithium's antisuicidal effect — possibly independent of mood stabilization itself — makes it a first-line choice for patients at elevated suicide risk.
Valproate (valproic acid) works by multiple mechanisms: it enhances GABA-ergic transmission (reducing neuronal excitability), blocks voltage-gated sodium channels, and has effects on calcium channels. Originally developed as an anticonvulsant, it is highly effective for acute mania and mixed episodes and is often preferred over lithium when rapid cycling or comorbid seizure disorders are present. Its major clinical concern is teratogenicity — valproate causes neural tube defects and cognitive impairment in offspring, making it contraindicated or requiring very careful risk discussion for individuals of childbearing potential. Liver function monitoring is required, particularly in the first six months of treatment.
Lamotrigine has a distinct profile: it works primarily by blocking glutamate release through sodium channel stabilization, and its efficacy is stronger for the depressive pole of bipolar than for mania. This makes it particularly valuable in bipolar II disorder or for patients whose illness is predominantly depressive. The major clinical concern is Stevens-Johnson syndrome (SJS), a severe, potentially fatal skin reaction that is risk-minimized by the essential clinical rule: lamotrigine must be titrated very slowly. Too-rapid dose escalation is the primary predictor of SJS. The choice among these agents is not interchangeable — clinical decision-making weighs episode polarity, cycling frequency, comorbidities, reproductive considerations, and tolerability to select and often combine agents across the mood stabilizer class.
No topics depend on this one yet.